Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities (2016)

Viridian Therapeutics, Inc.\DE has reported Preferred Stock Liabilities over the past 2 years, most recently at $23.1 million for Q4 2016.

  • Quarterly results put Preferred Stock Liabilities at $23.1 million for Q4 2016, down 62.0% from a year ago — trailing twelve months through Dec 2016 was $23.1 million (down 62.0% YoY), and the annual figure for FY2016 was $23.1 million, down 62.0%.
  • Preferred Stock Liabilities for Q4 2016 was $23.1 million at Viridian Therapeutics, Inc.\DE, down from $60.8 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for VRDN hit a ceiling of $60.8 million in Q4 2015 and a floor of $23.1 million in Q4 2016.